Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752762 | 0.88 | CYP3A4 (0.78) | CYP3A4MAPK1USP2SMN1; SMN2LMNA | |
| SCHEMBL28132534 | 0.87 | CYP3A4 (0.77) | CYP3A4MAPK1USP2SMN1; SMN2FASN | |
| SCHEMBL31055010 | 0.87 | CYP3A4 (0.77) | CYP3A4MAPK1USP2SMN1; SMN2FASN | |
| SCHEMBL679428 | 0.81 | CYP3A4 (0.68) | CYP3A4MAPK1USP2SMN1; SMN2LMNA | |
| SCHEMBL11420620 | 0.80 | CYP3A4 (0.67) | CYP3A4MAPK1USP2SMN1; SMN2FASN | |
| SCHEMBL18928951 | 0.78 | CYP3A4 (0.65) | CYP3A4MAPK1USP2SMN1; SMN2FASN | |
| SCHEMBL9752687 | 0.78 | CYP3A4 (0.65) | CYP3A4MAPK1USP2SMN1; SMN2FASN | |
| SCHEMBL684391 | 0.78 | CYP3A4 (0.64) | CYP3A4MAPK1USP2SMN1; SMN2LMNA | |
| SCHEMBL3660100 | 0.78 | CYP3A4 (0.63) | CYP3A4MAPK1USP2SMN1; SMN2LMNA | |
| SCHEMBL29664009 | 0.76 | CYP3A4 (0.61) | CYP3A4FASNKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20160151390-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3025714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9233107-B2 | Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) | BIOGEN MA INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20090312407-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies | FLORIDA A&M UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312407-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies | NRAS, KRAS, TP53 | CYP3A4 140/4885MAPK1 2154/4885USP2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.